China’s Drug Regulator Issues EUA for Sinopharm Vax in Children Aged 3 to 17

China’s Drug Regulatory Issues EUA for Sinopharm Vax in Children 3 to 17

China National Biotec Group (CNBG), a subsidiary of Sinopharm, recently announced via its WeChat account that regulatory authorities approved an emergency use authorization of the Sinopharm vaccine for children aged 3 to 17. China’s regulatory authorities have already approved the vaccine produced by Sinopharm targeting COVID-19. Although the vaccine has only been through Phase 1 and Phase 2 trials, the government declared that’s enough for the EUA as the drug showed “a high neutralizing antibody level among the age group, reports Global Times.

TrialSite notes that Global Times serves as a mouthpiece for the Communist Party in China. Via that medium, Sinopharm reports that 96.1% of those who received at least two doses of the vaccine produced significant antibodies against SARS-CoV-2. Moreover, they found no adverse events based on studies led by the provincial center for disease control and prevention of Central China’s Henan Province.

Phase 3 Adult Studies

Global Times reports that the Sinopharm vaccine went into Phase 3 clinical trials in the United Arab Emirates (UAE) in July 2020. While they declare that protection against severe protection is 100...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee